secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2022-09-28T23:59:59+00:00
Accession:  0001193125-22-252714
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura Biosciences doses first patient in Phase 1 study of AU-011 for bladder cancer
--------------------------------------------------------------------------------

- First patient dosed in Phase 1 study of belzupacap sarotalocan (AU-011) for non-muscle invasive bladder cancer (NMIBC).
- Phase 1 open-label trial to enroll approximately 23 adults; primary endpoint safety/tolerability.
- Initial Phase 1 data expected in 2023; CMO notes no major advances in NMIBC in over two decades.
- FDA granted Fast Track designation for AU-011 in NMIBC in June 2022.
- Approximately 70% of bladder cancer patients are diagnosed early with NMIBC (global).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000119312522252714/0001193125-22-252714-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000119312522252714/d363970d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-252714

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer